Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1997-04-04
1998-10-06
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514171, A61K 3156
Patent
active
058176500
ABSTRACT:
Systemic lupus erythematosus (SLE) is treated with dehydroepiandrosterone or its metabolite, sulfate ester, by itself or in combination with other therapies. Substantial improvement in SLE patients is observed during the course of treatment.
REFERENCES:
patent: 4628052 (1986-12-01), Peat
patent: 5001119 (1991-03-01), Schwartz et al.
patent: 5567696 (1996-10-01), McGuire et al.
Katcher et al., "Applied Therapeutics The Clinical Use of Drugs", third edition, published by Applied Therapeutics, Inc. (Spokane WA), pp. 1433-1439, 1983.
Van Wollenhoven, R. P., et al. "Treatment of Systemic Lupus Erythematosus with Dehydroepiandrosterone, A Pilot Study", Arthritis and Rheumatism, Abstract No. 126, 35(9)S55, 1992.
Vande Weile, et al., "Studies on the Secretion and Interconversation of the Androgens", College of Physicians and Surgeons of Columbia University, pp. 275-305, (1963).
Steinberg, et al., "Approach to the Study of the Role of Sex Hormones in Autoimmunity," Arthritis and Rheumatism, vol. 22, No. 11, pp. 1170-1176, (Nov. 1979).
Roubinian, et al., "Danazol's Failure to Suppress Autoimmunity in NZB/NZW F1 Mice," Arthritis and Rheumatism, vol. 22, No. 12, pp. 1399-1402 (Dec. 1979).
Jungers, et al., "Low Plasma Androgens in Women with Active or Quiescent Systemic Lupus Erythematosus," Arthritis and Rheumatism, vol. 25, No. 4, pp. 454-457 (Apr. 1982).
Alcocer-Varela, et al., "Deceased Production of and Response to Interleukin-2 by Cultured Lymphocytes from Patients with Systemic Lupus Erythematosus," Journal of Clinical Investigation, vol. 69, pp. 1388-1392 (Jun. 1982).
Linker-Israeli, et al., "Defective Production of Interleukin 1 and Interleukin 2 in Patents with Systemic Lupus Erythematosus (SLE)," The Journal of Immunology, vol. 130, No. 6, pp. 2651-2655 (Jun. 1983).
Lahita, et al., "Increased Oxidatioin of Testosterone in Systemic Lupus Erythematosus," Arthritis and Rheumatism, vol. 26, No. 12, pp. 1517-1521 (Dec. 1983).
Murakawa, et al., "Characterization of T Lymphocyte Subpopulations Responsible for Deficient Interleukin 2 Activity in Patients with Systemic Lupus Erythematosus," The Journal of Immunology, vol. 134, No. 1, pp. 187-195 (Jan. 1985).
Lucas, et al., "Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F1 Mice Fed Dehydroisoandrosterone," The Journal of Clinical Investigation, vol. 75, pp. 2091-2093 (Jun. 1985).
Barrett-Conner, et al., "A Prospective of Dehydroepiandrosterone Sulfate, Mortality and Cardiovascular Disease," The New England Journal of Medicine, vol. 315, No. 24, pp. 1519-1524 (Dec. 1986).
Lahita, et al., "Low Plasma Androgens in Women with Systemic Lupus Erythematosus," Arthritis and Rheumatism, vol. 30, No. 3, pp. 241-248 (Mar. 1987).
Regelson, et al., "Hormonal Intervention: `Buffer Hormones` or `State Dependency`," Annals of the New York Academy of Sciences, vol. 521, pp. 260-273 (1988).
West, et al., "Danazol for the Treatment of Refractory Autoimmune Thromobcytopenia in Systemic Lupus Erythematosus," Annals of Internal Medicine, vol. 108, pp. 703-706 (1988).
Cottran, et al., "Altered Lipid Metabolism and Induction of Peroxisomal Activity in NZB/W Mice Fed a Diet Containing 0.45% Dehydroisoandrosterone (DHA)," The Journal of Cell Biology, Abstract No. 684, vol. 107, No. 6: 122A (Dec. 1988).
Matsunaga, et al., "Effects of Dehydroisoandrosterone (DHA) Administration on Macrophage Function and Spleen Cell Mitogenic Response in NZB/W Female Mice," The Faseb Journal, Abstract No. 4371, vol. 2, No. 5: A1048 (Mar. 1988).
Matsunaga, et al., "Dehydroepiandrosterone Prevention of Autoimmune Disease in NZB/W F.sup.1 Mice: Lack of an Effect on Associated Immunological Abnormalities," Biochimica et Biophysica Acta, vol. 992, pp. 265-271 (1989).
Risdon, et al., "Mechanisms of Chemoprevention by Dietary Dehydroisoandrosterone: Inhibition of Lymphopoiesis," American Journal of Pathology, vol. 136, No. 4, pp. 759-769 (Apr. 1990).
Gutierrez-Ramos, et al., "Recovery from Autoimmunity of MRL/lpr Mice After Infection with an Interleukin-2/Vaccinia Recombinant Virus," Nature, vol. 346, pp. 271-274 (Jul. 1990).
Lahita, et al., "Experience with 19-Nortestosterone in the Therapy of Systemic Lupus Erhythematosus: Worsened Disease after Treatment with 19-Nortestoterone in Men and Lack of Improvement in Women," The Journal of Rheumatology, vol. 19, No. 4, pp. 547-555 (1992).
Van Wollenhoven, et al., "Treatment of Systemic Lupus Erythematosus with Dehydroepiandrosterone: Follow-Up from an Open-Label Clinical Trial," Arthritis and Rheumatism, Abstract No. C241, 36(9): S228 (1993).
Van Wollenhoven, et al., "Treatment of Systemic Lupus Erythematosus with Dehydroepiandrosterone: Interim Analysis of Double-Blinded Randomized, Placebo-Controlled Clinical Trial," Arthritis and Rheumatism, Abstract No. 322, 36(9): S92 (1993).
Engleman Edgar G.
McGuire, administratrix Linda R.
McGuire, deceased James L.
Van Vollenhoven Ronald F.
Dehlinger Peter J.
Henley III Raymond
Stratford Carol A.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Treatment of systemic lupus erythematosus with dehydroepiandrost does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of systemic lupus erythematosus with dehydroepiandrost, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of systemic lupus erythematosus with dehydroepiandrost will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77251